Anti-FBN3 functional antibody

Anti-FBN3 functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to FBN3/FBN3 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-SE0914-Ab-1/ GM-Tg-hg-SE0914-Ab-2Anti-Human FBN3 monoclonal antibodyHuman
GM-Tg-rg-SE0914-Ab-1/ GM-Tg-rg-SE0914-Ab-2Anti-Rat FBN3 monoclonal antibodyRat
GM-Tg-mg-SE0914-Ab-1/ GM-Tg-mg-SE0914-Ab-2Anti-Mouse FBN3 monoclonal antibodyMouse
GM-Tg-cynog-SE0914-Ab-1/ GM-Tg-cynog-SE0914-Ab-2Anti-Cynomolgus/ Rhesus macaque FBN3 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-SE0914-Ab-1/ GM-Tg-felg-SE0914-Ab-2Anti-Feline FBN3 monoclonal antibodyFeline
GM-Tg-cang-SE0914-Ab-1/ GM-Tg-cang-SE0914-Ab-2Anti-Canine FBN3 monoclonal antibodyCanine
GM-Tg-bovg-SE0914-Ab-1/ GM-Tg-bovg-SE0914-Ab-2Anti-Bovine FBN3 monoclonal antibodyBovine
GM-Tg-equg-SE0914-Ab-1/ GM-Tg-equg-SE0914-Ab-2Anti-Equine FBN3 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-SE0914-Ab-1/ GM-Tg-hg-SE0914-Ab-2; GM-Tg-rg-SE0914-Ab-1/ GM-Tg-rg-SE0914-Ab-2;
GM-Tg-mg-SE0914-Ab-1/ GM-Tg-mg-SE0914-Ab-2; GM-Tg-cynog-SE0914-Ab-1/ GM-Tg-cynog-SE0914-Ab-2;
GM-Tg-felg-SE0914-Ab-1/ GM-Tg-felg-SE0914-Ab-2; GM-Tg-cang-SE0914-Ab-1/ GM-Tg-cang-SE0914-Ab-2;
GM-Tg-bovg-SE0914-Ab-1/ GM-Tg-bovg-SE0914-Ab-2; GM-Tg-equg-SE0914-Ab-1/ GM-Tg-equg-SE0914-Ab-2
Products NameAnti-FBN3 monoclonal antibody
Formatmab
Target NameFBN3
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-FBN3 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-SE0914-Ag-1Recombinant multi-species FBN3 protein


    Target information

    Target IDGM-SE0914
    Target NameFBN3
    Gene ID84467,709446,485006,101094160,787458,100147616
    Gene Symbol and SynonymsFBN3
    Uniprot AccessionQ75N90
    Uniprot Entry NameFBN3_HUMAN
    Protein Sub-locationSecreted Protein/Potential Cytokines
    Category
    DiseaseN/A
    Gene EnsemblENSG00000142449
    Target ClassificationN/A

    The target: FBN3, gene name: FBN3, also named as . This gene encodes a memebr of the fibrillin protein family. Fibrillins are extracellular matrix molecules that assemble into microfibrils in many connective tissues. This gene is most highly expressed in fetal tissues and its protein product is localized to extracellular microfibrils of developing skeletal elements, skin, lung, kidney, and skeletal muscle. This gene is potentially involved in Weill-Marchesani syndrome. .



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.